Gemcitabine Injection, Powder, Lyophilized, For Solution
Product Images NDC 55111-687

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 55111-687). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1

Box packaging label for Gemcitabine for Injection, USP 200 mg/vial, a lyophilized powder for intravenous use. The label shows branding for Dr. Reddy's Laboratories Limited and includes instructions such as 'Must be diluted' and storage information. The label also mentions the product is a sterile single-use vial.*

FDA Label Image

Carton2

Gemcitabine for Injection USP 1 g/vial lyophilized powder for solution for intravenous use only. Packaging label shows the product name, strength, dosage form, route, and that it is a cytotoxic agent. The label is marked with Dr. Reddy's Laboratories Limited as the manufacturer, includes storage instructions, and indicates it must be diluted before use. Barcode and regulatory information are also visible.*

FDA Label Image

Figure1

A Kaplan-Meier survival curve chart depicting progression-free survival over time (months) comparing gemcitabine for injection with carboplatin versus carboplatin alone, each group with 178 patients. The vertical axis represents progression-free probability, while the horizontal axis shows progression-free survival in months up to about 42 months. The median progression-free survival is noted as 8.6 months for the combination therapy and 5.8 months for carboplatin alone with a p-value of 0.0038.*

FDA Label Image

Figure2

A Kaplan-Meier plot showing progression-free probability over time (months) for Gemcitabine for Injection versus Paclitaxel. The graph compares median time to documented disease progression, with Gemcitabine at 5.2 months and Paclitaxel at 2.9 months, including patient sample sizes (Gemcitabine/Paclitaxel N=267/262).*

FDA Label Image

Figure3

A Kaplan-Meier survival curve chart comparing survival probabilities over time (in months) for patients treated with gemcitabine/cisplatin versus cisplatin alone. The chart shows median survival of 9.0 months for gemcitabine/cisplatin and 7.6 months for cisplatin. It also includes 1-year survival percentages and statistical test results (Logrank and Wilcoxon p-values).*

FDA Label Image

Figure4

A survival curve chart depicting fraction surviving over survival time in months. The graph compares survival rates for Gemcitabine for injection and 5-FU, with Gemcitabine showing a higher fraction surviving over time.*

FDA Label Image

Structure

Chemical structure diagram of gemcitabine hydrochloride showing its molecular framework with nitrogen, oxygen, fluorine atoms, and hydroxyl groups indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.